Literature DB >> 1918981

Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines.

H Morimoto1, J T Safrit, B Bonavida.   

Abstract

Recent studies have demonstrated that diphtheria toxin (DTX) also mediates target cell lysis, and the mechanism of cytotoxicity has many features similar to those of cytotoxicity mediated by TNF-alpha. Thus, we hypothesized that DTX and TNF-alpha, used in combination, may result in either additive or synergistic cytotoxic activity. This was examined on three human ovarian carcinoma cell lines chosen for their differing sensitivities to TNF-alpha and DTX, i.e., 222, which is sensitive to both TNF-alpha and DTX, 222TR, a TNF-alpha-resistant DTX-sensitive variant of 222, and SKOV-3, which is resistant to both DTX and TNF-alpha. The simultaneous use of DTX and TNF-alpha at suboptimal concentrations resulted in synergistic cytotoxic activity against all three lines tested, thus overcoming the TNF-alpha resistance of 222TR and the double resistance of SKOV-3. DNA fragmentation was observed in all three lines treated with DTX and TNF-alpha and occurred as early as 4 h after treatment. Cycloheximide, actinomycin D, or emetine, at concentrations causing greater than 90% protein synthesis inhibition, did not result in cytotoxicity alone or synergy with TNF-alpha, suggesting that synergy by DTX was not due to its ability to inhibit protein synthesis. The use of energy poisons and pH conditions that inhibit DTX-mediated cytotoxicity resulted in the abrogation of synergy. These findings show that the two cytotoxic agents TNF-alpha and DTX, when used at suboptimal concentrations, synergize in their cytotoxic activity against sensitive and resistant cell lines. Because the SKOV-3 cell line used here is also resistant to chemotherapeutic drugs, combination treatment with DTX and TNF-alpha may be beneficial in overcoming drug resistance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918981

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Targeting diphtheria toxin and TNF alpha expression in ovarian tumors using the H19 regulatory sequences.

Authors:  Aya Mizrahi; Abraham Hochberg; Smadar Amiur; Jennifer Gallula; Imad Matouk; Tatiana Birman; Tally Levy; Sorin Ladimir; Patricia Ohana
Journal:  Int J Clin Exp Med       Date:  2010-09-21

2.  The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

Authors:  Laurence Booth; Jane L Roberts; Peter Samuel; Francesca Avogadri-Connors; Richard E Cutler; Alshad S Lalani; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

3.  Binding of tumour necrosis factor-alpha (TNF-alpha) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines.

Authors:  P Utaisincharoen; S Ubol; N Tangthawornchaikul; P Chaisuriya; S Sirisinha
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 4.  Platelet-activating factor and the cytokine network in inflammatory processes.

Authors:  B Bonavida; J M Mencia-Huerta
Journal:  Clin Rev Allergy       Date:  1994

5.  A polymerase chain reaction-based microsatellite typing assay used for tumor cell line identification.

Authors:  B L King; A Lichtenstein; J Berenson; B M Kacinski
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

6.  A monoclonal antibody targeted against epidermal growth factor receptor variant III enhances cisplatin efficiency.

Authors:  Na Li; Yuanyuan Chu; Liangqing Yao; Xiaojun Ying; Hua Jiang; Ming Zhou; Congjian Xu
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-02       Impact factor: 4.553

7.  ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.

Authors:  Roberta Traini; Gal Ben-Josef; Diana V Pastrana; Elizabeth Moskatel; Ashima K Sharma; Antonella Antignani; David J Fitzgerald
Journal:  Mol Cancer Ther       Date:  2010-06-29       Impact factor: 6.261

8.  Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality.

Authors:  T S Doi; M W Marino; T Takahashi; T Yoshida; T Sakakura; L J Old; Y Obata
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

9.  Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.

Authors:  Fernanda Musa; Amandine Alard; Gizelka David-West; John P Curtin; Stephanie V Blank; Robert J Schneider
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

10.  Cytotoxic properties of a new synthetic demethylpodophyllotoxin derivative, BN 58705, against human tumor cell lines.

Authors:  H Morimoto; P Principe; J P Robin; C Broquet; J M Mencia-Huerta; P Braquet; B Bonavida
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.